1
|
Wilson J, Fuller V, Benson G, Juroske D, Duvall E, Fu J, Pritchard J, Allen RW. Molecular assay for screening and quantifying DNA in biological evidence: the modified Q-TAT assay. J Forensic Sci 2010; 55:1050-7. [PMID: 20384933 DOI: 10.1111/j.1556-4029.2010.01371.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A method is described for the quantitation of total human and male DNA. Q-TAT utilizes end-point, multiplex polymerase chain reaction (PCR) amplification of the amelogenin and SRY loci to quantify DNA and incorporates a cloned nonhuman template to detect PCR inhibition. Standard curves of fluorescence from amelogenin or SRY amplicons were generated from amplification of known amounts of NIST traceable SRM-female or SRM-male DNA. Curves showed good linearity up to 500 pg of SRM-template (R(2) > 0.99) and reliably estimated total and male DNA content in casework samples. The nonhuman pRL(null) template included in each PCR was a sensitive indicator of known PCR inhibitors including EDTA, hemin, blue denim dye, and humic acid. Finally, the SRY amplicon was a sensitive indicator of male DNA and, in mixtures, could reliably estimate male DNA present in an excess of female DNA. The Q-TAT multiplex is a reliable quantitation method for forensic DNA typing.
Collapse
Affiliation(s)
- Jon Wilson
- Police Laboratory, Tulsa Police Department, Tulsa, OK, USA
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Cody DD, Nelson CL, Bradley WM, Wislez M, Juroske D, Price RE, Zhou X, Bekele BN, Kurie JM. Murine Lung Tumor Measurement Using Respiratory-Gated Micro-Computed Tomography. Invest Radiol 2005; 40:263-9. [PMID: 15829823 DOI: 10.1097/01.rli.0000160070.67270.05] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE The authors explored micro-computed tomography (micro-CT) to quantify lung tumor number and volume in a specific genetic mouse model for lung cancer. MATERIALS AND METHODS The authors used K-ras mice, which develop lung adenomas and adenocarcinomas through somatic activation of the K-ras oncogene. Tumor number measured using micro-CT and were compared at necropsy (n = 38 mice). Tumor volume measurement precision (n = 39 mice) and accuracy (multiple tumors from a single mouse) were evaluated. Serial lung tumor volume was assessed in a pilot group (n = 8) of mice in vivo. RESULTS Tumor number assessed at necropsy and using micro-CT were significantly correlated. Lung tumor volume measurements were both reproducible (2% operator variability) and accurate (6% average error). Strikingly, we observed both tumor growth and shrinkage within individual mice. CONCLUSION Serial measurements provided evidence of tumor heterogeneity, an unexpected finding given the uniformity of the initiating genetic event. Micro-CT may become a powerful tool for murine lung cancer research in vivo.
Collapse
Affiliation(s)
- Dianna D Cody
- Department of Imaging Physics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005; 65:226-35. [PMID: 15665299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
Epidermal growth factor receptor (EGFR) is occasionally amplified and/or mutated in non-small cell lung cancer (NSCLC) and can be coexpressed with other members of the HER receptor family to form functional heterodimers. We therefore investigated lung cancer cell lines for alterations in EGFR gene copy number, enhanced expression of EGFR and other HER family members, and EGFR coding sequence mutations and correlated these findings with response to treatment with the EGFR inhibitors and the kinetics of ligand-induced signaling. We show here that somatic deletions in the tyrosine kinase domain of EGFR were associated with increased EGFR gene copy number in NSCLC. Treatment with the specific EGFR tyrosine kinase inhibitors (TKI) gefitinib or erlotinib or the EGFR inhibitory antibody cetuximab induced apoptosis of HCC827, a NSCLC cell line with EGFR gene amplification and an exon 19 deletion. H1819, a NSCLC cell line that expresses high levels of EGFR, ErbB2, and ErbB3 but has wild-type EGFR, showed intermediate sensitivity to TKIs. In both cell lines, ligand-induced receptor tyrosine phosphorylation was delayed and prolonged and AKT was constitutively phosphorylated (but remained inhibitable by EGFR TKI). Thus, in addition to EGFR mutations, other factors in NSCLC cells, such as high expression of ErbB family members, may constitutively activate AKT and sensitize cells to EGFR inhibitors.
Collapse
Affiliation(s)
- Joseph Amann
- Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP. Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer. Cancer Res 2005. [DOI: 10.1158/0008-5472.226.65.1] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Epidermal growth factor receptor (EGFR) is occasionally amplified and/or mutated in non–small cell lung cancer (NSCLC) and can be coexpressed with other members of the HER receptor family to form functional heterodimers. We therefore investigated lung cancer cell lines for alterations in EGFR gene copy number, enhanced expression of EGFR and other HER family members, and EGFR coding sequence mutations and correlated these findings with response to treatment with the EGFR inhibitors and the kinetics of ligand-induced signaling. We show here that somatic deletions in the tyrosine kinase domain of EGFR were associated with increased EGFR gene copy number in NSCLC. Treatment with the specific EGFR tyrosine kinase inhibitors (TKI) gefitinib or erlotinib or the EGFR inhibitory antibody cetuximab induced apoptosis of HCC827, a NSCLC cell line with EGFR gene amplification and an exon 19 deletion. H1819, a NSCLC cell line that expresses high levels of EGFR, ErbB2, and ErbB3 but has wild-type EGFR, showed intermediate sensitivity to TKIs. In both cell lines, ligand-induced receptor tyrosine phosphorylation was delayed and prolonged and AKT was constitutively phosphorylated (but remained inhibitable by EGFR TKI). Thus, in addition to EGFR mutations, other factors in NSCLC cells, such as high expression of ErbB family members, may constitutively activate AKT and sensitize cells to EGFR inhibitors.
Collapse
Affiliation(s)
- Joseph Amann
- 1Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
| | - Shailaja Kalyankrishna
- 2Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
| | | | - Joyce E. Ohm
- 1Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
| | - Luc Girard
- 3Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Hisayuki Shigematsu
- 3Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Michael Peyton
- 3Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Denise Juroske
- 2Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
| | - Yuhui Huang
- 1Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
| | | | - Young H. Kim
- 4Department of Pathology, Stanford University School of Medicine, Stanford, California; and
| | - Jonathan R. Pollack
- 4Department of Pathology, Stanford University School of Medicine, Stanford, California; and
| | | | - Adi Gazdar
- 3Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas
| | - John D. Minna
- 3Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Jonathan M. Kurie
- 2Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
| | | |
Collapse
|